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DOI 10.1016/j.ccr.2011.11.024SUMMARYThe functional role of pericytes in cancer progression remains unknown. Clinical studies suggest that low
numbers of vessel-associated pericytes correlated with a drop in overall survival of patients with invasive
breast cancer. Using genetic mouse models or pharmacological inhibitors, pericyte depletion suppressed
tumor growth but enhanced metastasis. Pericyte depletion was further associated with increased hypoxia,
epithelial-to-mesenchymal transition (EMT), and Met receptor activation. Silencing of Twist or use of a Met
inhibitor suppressed hypoxia and EMT/Met-driven metastasis. In addition, poor pericyte coverage coupled
with high Met expression in cancer cells speculates the worst prognosis for patients with invasive breast
cancer. Collectively, our study suggests that pericytes within the primary tumor microenvironment likely
serve as important gatekeepers against cancer progression and metastasis.INTRODUCTION
Metastasis is the leading cause of death in cancer patients. The
formationof secondary tumorsormetastasis is greatly influenced
by multifaceted tumor-stroma interactions, in which stromal
components of the tumor microenvironment can influence the
behavior of the cancer cells (Coussens et al., 2000; Joyce,
2005; Thiery, 2009). While cancer cell-autonomous changes
are undoubtedly critical for cancer progression and metastasis,
the functional contribution of stromal cells is still emerging.
Pericytes are an integral component of the tissue vasculature.
As perivascular stromal cells, pericytes provide structural
support to blood vessels and regulate tissue physiology via its
influence on vascular stability (Dore-Duffy and Cleary, 2011;
Kim et al., 2006). Due to their essential function in vascular devel-
opment, pericytes are also speculated to play an important roleSignificance
Pericyte coverage and its relation tometastasis are poorly unde
vasculature serves as a key negative regulator of metastasis. C
of vessel-associated pericytes exhibit a high mortality rate.
changes to determine the rate of cancer progression and met
66 Cancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc.in tumor angiogenesis. Angiogenesis is required for the growth of
tumors, and VEGF-mediated proliferation andmigration of endo-
thelial cells is critical for the generation of new capillaries, which
is further supported by the recruitment of pericytes (Raza et al.,
2010). Some studies have explored strategies that target both
endothelial cells and pericytes (Bergers et al., 2003; Lu et al.,
2007) or pericytes alone (Lu et al., 2007; Ozerdem, 2006a) to
inhibit tumor angiogenesis and tumor growth. However, clinical
data correlates low pericyte coverage with poor patient prog-
nosis (O’Keeffe et al., 2008; Stefansson et al., 2006; Yonenaga
et al., 2005), and disruption of pericytes has also been suggested
to enhance metastasis (Xian et al., 2006).
The growth of tumors is often associated with defective tumor
vasculature that cannot keep up with the overall oxygen and
metabolic needs, ultimately resulting in tumor hypoxia (Harris,
2002; Semenza, 2003). Diminished oxygen levels lead to therstood. This study suggests that pericyte coverage on tumor
linical studies suggest that cancer patients with low numbers
Cancer cell autonomous changes cooperate with stromal
astasis.
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(Pouysse´gur et al., 2006), and hypoxia and HIF1a expression
are correlated with poor prognosis and metastasis in cancer
patients (Birner et al., 2000; Bos et al., 2003; Brizel et al., 1997;
Vleugel et al., 2005). Hypoxia induces epithelial-to-mesen-
chymal transition (EMT) of cells specifically via HIF1a activation
of the master regulator of EMT Twist (Sun et al., 2009; Yang
et al., 2008), which is suggested to play an essential role in
promoting metastasis (Yang et al., 2004).
Met, the receptor for hepatocyte growth factor (HGF), is also
a key promoter of EMT (Birchmeier et al., 2003). Furthermore,
the Met promoter contains HIF1a binding sites and is regulated
by both hypoxia and HIF1a (Hara et al., 2006; Hayashi et al.,
2005; Pennacchietti et al., 2003). HGF/Met expression is also
upregulated in many cancers (Di Renzo et al., 1991), correlating
with disease progression and metastasis (Di Renzo et al., 1995;
Kenworthy et al., 1992) (Natali et al., 1993).
Using genetically engineered mouse models (GEMMs) and
pharmacological targeting of pericytes, we examined whether
pericyte deficiency positively or negatively affects metastasis
and explored possible underlying mechanisms.
RESULTS
Low Pericyte Coverage Is Associated with Invasive
Breast Cancer and Correlates with Decreased
Patient Survival
Pericyte coverage of the tumor vasculature was evaluated in
tissue samples from breast cancer patients with invasive ductal
carcinoma via immunostaining for NG2, a vascular pericytes
marker (Bergers and Song, 2005; Jain, 2003; Ozerdem et al.,
2002; Schlingemann et al., 1990; Sennino et al., 2007), andCD31,
a marker for endothelial cells (Newman, 1994). The percentage
of CD31+ vessels associated with NG2 staining was quantified
using morphometric analysis. Among various clinical character-
istics, low pericyte coverage was significantly associated with
the presence of distant metastasis (Table S1 available online).
Moreover, the degree of pericyte coverage also significantly
correlated with disease progression and overall survival (Fig-
ure S1A). Patientswith no detectable pericyte coverage on tumor
vessels exhibited a shorter disease-free survival and lower rate of
overall survival than patients with greater pericyte coverage.
Pericyte Depletion Inhibited Tumor Growth
but Produced Defective Tumor Vasculature
and Increased Metastasis
To functionally assess the role of pericytes in tumor progression
and metastasis, we generated transgenic mice that express viral
thymidine kinase (tk) under control of the NG2 promoter (NG2-tk
mice) (Figure S1B). Ganciclovir (GCV) treatment of NG2-tk mice
resulted in the selective ablation of proliferating NG2+ cells due
to incorporation of GCV nucleoside analog during replication
leading to irreversible DNA synthesis arrest. To assess the
specificity of the NG2 promoter for expression in NG2+ cells,
we generated NG2-YFP transgenic mice that express yellow
fluorescent protein (YFP) under the control of the same NG2
promoter sequence and found that NG2-YFP expression colo-
calized with NG2 antibody staining in 4T1 mammary tumors
(Figures S1B and S1C). To determine the efficacy of theNG2-tk transgene, in vitro culture of NG2+ cells from NG2-tk
and wild-type (WT) mice were treated with varying GCV concen-
trations (Figure S1D). Dose-dependent ablation of NG2+ cells
was observed, with 75% ablation at 500 mM GCV.
4T1-GFP cancer cells were implanted into the mammary
fat pad of NG2-tk mice and wild-type littermates. Primary
tumor growth was monitored and daily GCV injections were initi-
ated when tumors reached 500 mm3 and continued until
tumors reached 2,000 mm3 (Figure 1A). Tumor volumes
decreased upon initiation of GCV treatment in the NG2-tk mice
and remained significantly smaller until the experimental
endpoint (Figure 1B). The number of NG2+ cells, CD31+ cells,
and percent vessel-associated NG2+ cells in the primary tumors
of NG2-tk+GCV mice were significantly reduced when com-
pared to control GCV-treated wild-type littermates (WT+GCV
mice) (Figure 1C). To investigate whether pericyte depletion
was associated with vascular abnormalities, we infused tumor-
bearing mice with FITC-conjugated dextran and observed
a greater amount of extravascular FITC-dextran in pericyte-
depleted tumors (Figure 1D).
While pericyte ablation reduced primary tumor growth, 4T1
tumor-bearing NG2-tk+GCV mice exhibited increased lung
metastasis when compared to WT+GCV mice (Figure 1E).
FACS and quantitative PCR analysis of genomic DNA for the
cancer cell-associated GFP gene revealed that the number of
circulating cancer cells and metastatic cancer cells in the lungs
was greater in NG2-tk+GCV mice than in WT+GCV mice.
Reduced tumor size and increased metastasis were also
observed when pericytes were ablated in the MMTV-PyMT
spontaneous mammary tumor model using GCV-treated
MMTV-PyMT/NG2-tk double transgenic mice (Figures 1F and
1G). However, upon intravenous injection of 4T1 cancer cells
into NG2-tk+GCV and WT+GCV mice, pericyte ablation had no
significant effects on metastasis in the absence of a primary
tumor (Figure S1E).
PDGFRb has also been used as a marker to identify pericytes
(Dore-Duffy, 2008; Hellstro¨m et al., 1999; Liebner et al., 2000;
Ozerdem et al., 2001a; Xian et al., 2006). To validate the prome-
tastatic effects of pericyte depletion observed in NG2-tk+GCV
mice, we generated PDGFRb-tk mice in which viral thymidine
kinase is expressed under the PDGFRb promoter as an alterna-
tive model for pericyte depletion (Figure S2A). To assess
the specificity of the PDGFRb promoter, we also generated
PDGFRb-RFP mice in which red fluorescent protein (RFP) is ex-
pressed under the same PDGFRb promoter element (Figures
S2A and S2B) and found that PDGFRb-RFP expression colocal-
ized with PDGFRb antibody staining in 4T1 tumors. To determine
the efficacy of the PDGFRb-tk transgene, in vitro culture of
PDGFRb+ cells from PDGFRb-tk and WT mice were subjected
to increasing concentrations of GCV (Figure S2C). Dose-depen-
dent ablation of PDGFRb+ cells was observed, with 60%ablation
at 50 mM GCV.
4T1 cancer cells were implanted into the mammary fat pad of
PDGFRb-tk mice andWT littermates. Tumor volumes decreased
upon initiation of GCV treatment in PDGFRb-tk mice and
remained significantly smaller until the experimental endpoint
when compared to WT+GCV mice (Figures 2A and 2B).
However, metastasis was greatly enhanced following ablation
of PDGFRb+ cells (Figure 2C). Immunostaining with PDGFRbCancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc. 67
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Figure 1. Reduced Tumor Growth and Increased Metastasis after Depletion of Vessel-Associated NG2+ Cells
(A) Orthotopic implantation of 4T1 cancer cells in NG2-tk mice and wild-type littermates, with daily ganciclovir (GCV) or saline (PBS) injections beginning when
tumors reached 500 mm3.
(B) Tumor volumes over the experimental time course.
(C) Representative images of tumor sections fromWT+GCV and NG2-tk+GCV mice immunolabeled for NG2 (green)/CD31 (red), and quantification of number of
NG2+ cells, CD31+ cells, and percent vessel-associated NG2+ cells in each group. DAPI = nuclei. Scale bar, 50 mm. High-magnification images are located in the
upper right corner. Scale bar, 10 mm.
Cancer Cell
Pericyte and Metastasis
68 Cancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc.
Cancer Cell
Pericyte and Metastasisantibody in the tumors of PDGFRb-tk+GCV mice revealed 80%
reduction in vessel-associated PDGFRb+ cells (Figure 2D).
PDGFRb shares90% colocalization with NG2 on tumor vascu-
lature (Sugimoto et al., 2006), and vessel-associated NG2+ cells
were also reduced by 80% in the tumors of PDGFRb-tk+GCV
mice (Figure 2D). The overall pericyte coverage (assessed by
vessel-associated NG2+/PDGFRb+ double-positive cells) and
the number of CD31+ cells were reduced in PDGFRb-tk+GCV
mice when compared to WT+GCV mice (Figure 2D).
As an alternative model for inhibiting PDGFRb+ cells, 4T1
tumor-bearing mice were treated with PDGFRb-specific anti-
bodies to suppress PDGFRb activity. PDGFRb antibody treat-
ment significantly decreased tumor volume and increasedmeta-
static burden (Figures 2E and 2F), in associationwith a significant
reduction in the percent vessel-associated PDGFRb+ cells
(Figure 2G).
EnhancedHypoxia, HIF1aExpression, andEMTProgram
in Pericyte-Depleted Tumors
To gain insight into the molecular mechanisms associated with
increased metastasis resulting from pericyte depletion, we per-
formed gene expression profiling of tumors from NG2-tk+GCV
and WT+GCV mice. We employed genealogy analysis to identify
significantly upregulated genes [grouped as pathways (Table S2)
and network processes (Table S3)] in NG2-tk+GCV mice when
compared to WT+GCV mice. The overlapping processes identi-
fied were (1) response to hypoxia, (2) response to stress, and (3)
cell motion/migration (Table S3). Reduced pericyte coverage
can decrease vessel stability and increase hypoxia (Huang et al.,
2010). In concordance, pericyte depletion in the NG2-tk+GCV
mice induced a gene expression profile that reflected a hypoxic
state. We assessed hypoxia levels by examining pimonidazole
adduct formation in the tumors of NG2-tk+GCV and WT+GCV
mice and found increased hypoxic levels in theNG2-tk+GCVperi-
cyte-depleted tumors (Figure 3A). In addition, expression of the
hypoxia-inducible transcription factorHIF1awas also significantly
increased in the tumors of NG2-tk+GCV mice (Figure 3B).
The exact mechanism connecting hypoxia and cancer inva-
siveness remains unknown; however, several have been
proposed (Dachs and Tozer, 2000; Gupta and Massague´,
2006; Rofstad, 2000; Yang et al., 2008). Because cell motion/
migrationwas identified as one of the primary processes upregu-
lated by NG2-tk+GCV tumors in the gene expression profiling
analysis, we hypothesized that EMT may be a mechanism con-
necting hypoxia and cancer invasiveness. Further examination
of the microarray data revealed that the expression of many
EMT-associated genes were upregulated in NG2-tk+GCV
tumors when compared to WT+GCV tumors (Table S4). To iden-(D) Representative images of tumor sections immunolabeled for CD31 (red) and
50 mm.
(E) Representative images of H&E-stained lung sections. Scale bar: 10 mm. Arrows
are located in the upper right corner. Scale bar: 50 mm. Percent metastatic area, n
relative GFP content in lungs of NG2-tk+GCV mice compared to WT+GCV mice
(F) MMTV-PyMT/WT and MMTV-PyMT/NG2-tk female mice were treated with G
time.
(G) Representative images of H&E-stained lung sections of MMTV-PyMT/WT+G
metastatic nodules. Percent metastatic area and number of metastatic lung nod
nonsignificant.
See also Figure S1 and Table S1.tify epithelial cells undergoing EMT, tumors from NG2-tk+GCV
andWT+GCVmicewere immunostained for the epithelial marker
Cytokeratin-8 (CK8) and the mesenchymal marker aSMA; the
number of CK8+/aSMA+ double-positive cells was significantly
increased in NG2-tk+GCV pericyte-depleted tumors (Figure 3C).
Next, we performed quantitative RT-PCR and confirmed that
expression of CK8 was significantly downregulated, while tran-
scription factors associated with EMT induction, such as
Twist and Snail, were significantly upregulated in NG2-tk+GCV
tumors (Figure 3D). Other epithelial genes such as E-cadherin
and a-catenin were also downregulated, while genes driving
mesenchymal phenotype such as Slug, Lox, and Fibronectin
were upregulated.
In agreementwith thedata from theNG2-tk+GCVmice, tumors
from MMTV-PyMT/NG2-tk+GCV mice revealed increased
hypoxia along with increased numbers of CK8+/aSMA+ double-
positive cells, reduced E-cadherin expression, and increased
Twist and Snail expression, when compared to tumors from
MMTV-PyMT/WT+GCV mice (Figures 3E–3G). Tumors from
PDGFRb-tk+GCV mice also showed increased hypoxia,
increased HIF1a expression, and acquisition of an EMT program
shift when compared to control mice (data not shown).
The transcription factor Twist has been termed the master
regulator of EMT (Yang et al., 2004). To evaluate whether inhibi-
tion of EMT via silencing of Twist abrogates the metastatic
phenotype seen in NG2-tk+GCVmice, we orthotopically injected
4T1 cancer cells with stably-silenced Twist (two different clones
of 4T1-twist shRNA) into NG2-tk+GCV and WT+GCV mice.
Tumor volume in 4T1-twist shRNA tumor-bearing NG2-tk+GCV
mice was reduced when compared to 4T1-twist shRNA tumor-
bearingWT+GCVmice (Figure 4A). Moreover, metastatic burden
was decreased in 4T1-twist shRNA tumor-bearing WT+GCV
mice when compared to 4T1 tumor-bearing WT+GCV mice,
while metastasis was further suppressed in 4T1-twist shRNA
tumor-bearing NG2-tk+GCV mice (Figures 4B–4E).
Met Protooncogene Activation in Pericyte-Depleted
Tumors
Quantitative RT-PCR for Met revealed significantly increased
Met expression in NG2-tk+GCV tumors when compared to
WT+GCV tumors (Figure 5A). Additionally, increased phosphor-
ylation of Met was also observed in tumors from NG2-tk+GCV
and MMTV-PyMT/NG2-tk+GCV mice when compared to
tumors from control mice (Figures 5B and 5C), as well as in
PDGFRb-tk+GCV mice (data not shown).
Next, we explored whether pharmacological targeting of Met
can suppress metastasis in pericyte-ablated mice. Treatment
of MMTV-PyMT/NG2-tk mice with both GCV and the Metquantitative analysis of extravascular FITC-dextran. DAPI = nuclei. Scale bar,
point to metastatic nodules. High-magnification images of metastatic nodules
umber of metastatic lung nodules, number of 4T1-GFP+ cells in the blood, and
.
CV when tumors reached 500 mm3 and tumor volumes measurements over
CV and MMTV-PyMT/NG2-tk+GCV mice. Scale bar: 10 mm. Arrows point to
ules. Error bars display SEM; asterisks denote significance (*p % 0.05). NS,
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Figure 2. Reduced Tumor Growth and Increased Metastasis after Depletion of Vessel-Associated PDGFRb+ Cells
(A) Orthotopic implantation of 4T1 cancer cells into PDGFRb-tk mice and wild-type littermates, with daily ganciclovir (GCV) injections beginning when tumors
reached 500 mm3.
(B) Tumor volumes over the experimental time course.
(C) Representative images of H&E-stained lung sections. Scale bar, 10 mm. Arrows point to metastatic areas. High-magnification images of metastatic nodules
are located in the upper right corner. Scale bar: 50 mm Percent metastatic area and number of metastatic lung nodules.
(D) Representative images of immunostaining for PDGFRb (red) and NG2 (green) tumor sections. DAPI = nuclei. Scale bar, 50 mm. Quantitative assessment of
vessel-associated PDGFRb+, NG2+, PDGFRb+/NG2+ double positive, and CD31+ cells in 4T1 tumors from PDGFRb-tk+GCV and WT+GCV mice.
(E) Tumor volumes over the experimental time course in mice treated with anti-PDGFRb antibody or control IgG.
(F) Number of metastatic lung nodules.
(G) Representative images of tumor sections immunolabeled for PDGFRb (green)/CD31 (red) in IgG-treated and anti-PDGFRb-treated mice, and quantification of
vessel-associated PDGFRb+ cells in the tumors; scale bar, 50 mm. Insets are magnified images of selected area.
Scale bar, 10 mm. Error bars display SEM; *p% 0.05. See also Figure S2.
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Pericyte and Metastasisinhibitor PF2341066 completely suppressed the enhanced
metastasis ofMMTV-PyMT/NG2-tkmice treated with GCV alone
(Figures 5D–5F). The baseline lung metastasis observed in the
control tumors (without pericyte depletion, hypoxia, HIF-1a
expression, Met activation, and EMT) did not respond to Met
inhibition.70 Cancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc.Enhanced Metastasis upon Pericyte Targeting
Using Pharmacological Inhibitors Is Suppressed
by Concomitant Met Inhibitor Treatment
Many studies have reported that imatinib (which targets
pericytes via PDGFRb) and sunitinib (which targets both endo-
thelial cells and pericytes via VEGFR1, VEGFR2, VEGFR3, and
Cancer Cell
Pericyte and MetastasisPDGFRb), drugs currently in clinical use, can inhibit tumor
progression (Bergers et al., 2003; Ebos et al., 2009; Lu et al.,
2007; Mendel et al., 2003; Pa`ez-Ribes et al., 2009; Pietras and
Hanahan, 2005); however, there have been limited studies exam-
ining their effects on metastasis. Treatment with sunitinib and
another receptor tyrosine kinase inhibitor sorafenib have been
demonstrated to increase metastasis in animal tumor models
(Ebos et al., 2009; Pa`ez-Ribes et al., 2009); however, the molec-
ular mechanism for which remains largely unknown. Therefore,
we examined whether imatinib and sunitinib enhance metastasis
due to mechanisms similar to shown above.
4T1 tumor-bearing mice were treated with either imatinib or
sunitinib. Imatinib treatment reduced pericyte coverage (as
determined by vessel-associated NG2+/PDGFRb+ double-posi-
tive cells) by more than 60% (Figure S3A). In concordance with
previous reports (Lu et al., 2007), decreased pericyte coverage
was not accompanied by net reduction of tumor vessels (Fig-
ure S3A). Quantitative RT-PCR showed negligible expression
levels of c-Kit and Abl1 (additional targets of imatinib) in 4T1
tumors, and their expression remained unchanged upon imatinib
treatment (Figure S3A). Sunitinib treatment led to reduced
numbers of both NG2+/PDGFRb+ double-positive cells and
CD31+ endothelial cells (Figure S3A).
4T1 tumor-bearing mice treated with sunitinib exhibited
reduced tumor volume and growth with increased levels of
apoptosis, while imatinib-treated tumor-bearing mice revealed
similar tumor growth kinetics when compared to mice treated
with PBS-vehicle (Figures 6A–6C). Analysis of lungs revealed
a significantly higher level of metastatic burden in both the
imatinib-treated and sunitinib-treated groups (Figure 6D).
Quantification of FITC-dextran revealed increased amount of
extravascular dextran in the tumors of imatinib-treated and suni-
tinib-treated mice (Figure 6E). Furthermore, tumors in imatinib-
treated and sunitinib-treated mice showed significant increase
in hypoxia as assessed by pimonidazole staining (Figure 6F),
as well as increased expression of HIF1a (Figure 6G). Similar to
results obtained with the transgenic mice, however, imatinib or
sunitinib treatment had no significant effects on metastasis
when 4T1 cells were injected intravenously (Figure S3B).
Next, we evaluatedwhether pharmacological targeting of peri-
cytes also induced an EMT program in the cancer cells. Tumors
from imatinib-treated and sunitinib-treated mice exhibited
increased numbers of CK8+/aSMA+ double-positive cells when
compared to tumors from PBS-treated mice (Figure 6H). In addi-
tion, quantitative RT-PCR showed significant downregulation
of E-cadherin, while Twist and Snail were upregulated (Fig-
ure 6I). To address whether inhibition of EMT can suppress the
increased metastatic phenotype seen after pharmacological
targeting of pericytes, mice were implanted with 4T1-twist
shRNA cells and treated with imatinib. Silencing of Twist was
able to suppress the imatinib-induced EMT and metastasis
without significant effects on primary tumor growth (Figure S3C).
Levels of Met and phosphorylated Met were also increased in
tumors of imatinib-treated and sunitinib-treated mice when
compared to PBS-treated mice (Figures S4A and S4B). Tumors
from PBS-treated mice showed phosphorylated Met expression
predominantly in the vascular wall, while tumors from imatinib-
treated and sunitinib-treated mice exhibited significantly higher
levels of phosphorylated Met in the cancer cells. Pharmacolog-ical targeting of Met using PF2341066 inhibited the EMT
program shift and suppressed metastasis in imatinib-treated
and sunitinib-treated mice (Figures 7A–7F), despite retaining
the imatinib- or sunitinib-induced changes in vessel integrity
and tumor hypoxia (Figures 7G–7I). PF2341066 treatment of
imatinib-treated and sunitinib-treated mice successfully in-
hibited both Met and phosphorylated Met levels (Figure S4B).
Although PF2341066 is also an inhibitor of ALK (Zou et al.,
2007), quantitative RT-PCR (data not shown) and immunostain-
ing revealed that ALK was not expressed in 4T1 tumors with or
without PF2341066 treatment (Figure S4C). The baseline tumor
weight and lung metastasis observed in the control tumors
(without pericyte deficiency, hypoxia, HIF1a expression, Met
activation, and EMT) did not respond to Met inhibition alone
(Figure S4D).
To further investigate whether targeting pericytes leads to
increased metastasis in other tumor types, we subcutaneously
implanted B16F10mousemelanoma cells into C57Bl6mice (Fig-
ure S4E) and orthotopically implanted 786-O human renal cell
carcinoma cells under the renal capsule of nude mice (Fig-
ure S4F). The mice were then treated with PBS, sunitinib,
PF2341066 or a combination of both sunitinib and PF2341066.
Sunitinib treatment led to reduced B16F10 tumor volume and
weight but led to an increase in metastasis. Sunitinib-treated
tumors also showed increase in hypoxia, phosphorylated Met,
and induction of EMT. Treatment with PF2341066 did not affect
primary tumor volume and weight; however, concomitant treat-
ment with PF2341066 and sunitinib significantly suppressed
metastasis, despite hypoxia remaining high in these tumors.
Similarly, mice with RCC tumors treated with sunitinib showed
increased lung metastasis, increased hypoxia, increased
phosphorylated Met, and enhanced EMT program. Concomitant
treatment of RCC tumor-bearing mice with sunitinib and
PF2341066 suppressed metastasis and EMT despite high levels
of hypoxia. Sunitinib-treated mice intravenously injected with
RCC (to bypass the primary tumor), however, showed signifi-
cantly reducedmetastasiswhen compared to PBS-treatedmice.
To explore the impact of targeting only endothelial cells on
metastasis without targeting pericytes, RCC tumor-bearing
mice were treated with anti-human VEGF-A blocking antibody
(Bevacizumab) and 4T1 tumor-bearing mice with anti-mouse
VEGF-A blocking antibody. Bevacizumab treatment led to
decreased tumor volume; however, metastasis was unchanged
(Figure S4G). Tumors from bevacizumab-treated mice did not
show an increase in hypoxia or Met activation (Figure S4G).
4T1 tumor-bearing mice treated with VEGF-A antibody showed
reduced tumor growth and metastasis when compared to
control mice (Figure S4H). Similar results were obtained when
pancreatic neuroendocrine (PNET) and RCC tumor-bearing
mice were treated with endogenous inhibitors of angiogenesis
that target endothelial cells, such as tumstatin and endostatin
(data not shown; Xie et al., 2011).
Loss of Pericytes Coupled with High Met Expression
Is Associated with Decreased Survival of Breast
Cancer Patients
Our experiments with mice suggested that loss of pericytes
leads to enhanced tumor hypoxia and metastasis via increased
Met expression in cancer cells. We evaluated breast cancerCancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc. 71
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Figure 3. Increase in Hypoxia and EMT in Pericyte-Depleted Tumors
(A) Hypoxia was detected by immunohistochemistry staining of pimonidazole adducts in 4T1 tumor sections from NG2-tk+GCV and WT+GCV mice. Nuclear
counterstain: hematoxylin stain. Quantitative analysis of the percent hypoxic area per visual field.
(B) Immunostaining for HIF1a. DAPI = nuclei. Quantification of HIF1a immunostaining and western blot analysis for HIF1a expression; GAPDH is used as an
internal control.
(C) EMT as detected by immunofluorescent staining for Cytokeratin 8 (red) and aSMA (green). DAPI = nuclei. Arrows point to CK8+/aSMA+ double-positive cells.
Quantification of EMT is plotted as fold change in the number of CK8+/aSMA+ double-positive cells per visual field.
(D) Quantitative RT-PCR for a-catenin,Cytokeratin 8 (CK8), E-cadherin, Fibronectin, Slug, Snail, Twist, and Lox comparing expression levels in tumor tissues from
NG2-tk+GCV mice relative to WT+GCV mice and plotted as log10 relative expression.
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Figure 4. Decreased Metastasis in Mice with Pericyte-Depleted Tumors after Inhibition of EMT
(A) Tumor volumes over the experimental time course in WT+GCV and NG2-tk+GCV mice implanted with 4T1 or 4T1-Twist shRNA cells.
(B–D) Representative photomicrographs of H&E-stained lung sections of WT+GCV and NG2-tk+GCV mice implanted with (B) 4T1 cells, (C) 4T1-Twist shRNA
cells-clone 5 and (D) 4T1-Twist shRNA cells-clone 7. Arrows point to metastatic nodules.
(E) Quantification of metastatic area.
Error bars display SEM; asterisks denote significance (*p% 0.05). NS, nonsignificant. Scale bar, 50 mm.
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Pericyte and Metastasissamples for pericyte coverage, HIF1a expression and Met
expression. Invasive ductal carcinoma (IDC) patients with high
levels of HIF1a exhibited poor prognosis with diminished
disease-free survival, as has been also suggested by other
studies (Baba et al., 2010; Koukourakis et al., 2002; Vleugel
et al., 2005). While high Met expression in cancer cells was asso-
ciated with a drop in disease-free and overall survival, the
coupling of poor pericyte coverage together with high Met
expression correlated with an additional drop in disease-free
and overall survival (Figures 8A and 8B). Furthermore, pericyte(E) Representative images of pimonidazole adducts staining (hypoxia). Nuclear co
visual field.
(F) EMT as detected by immunofluorescent staining for Cytokeratin 8 (red) and aS
Quantification of EMT plotted as the number of CK8+/aSMA+ double-positive ce
(G) Quantitative RT-PCR for E-cadherin, Snail, and Twist plotted as log10 relative
Scale bar, 50 mm. See also Tables S2–S4.coverage coupled with Met expression correlated with breast
cancer stage, depth of invasion, and the presence of distant
metastasis (Figure 8C).
DISCUSSION
Tumors induce angiogenesis to generate new blood vessels
(Folkman, 1971, 1974, 1995; Hanahan and Weinberg, 2000),
and pericytes are important structural and functional compo-
nents of blood vessels (Dore-Duffy and Cleary, 2011). In normalunterstain: hematoxylin staining. Quantification of the percent hypoxic area per
MA (green). DAPI = nuclei. Arrows point to CK8+/aSMA+ double-positive cells.
lls per visual field.
expression. Error bars display SEM; asterisks denote significance (*p% 0.05).
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Figure 5. Suppression of Metastasis in Pericyte-Ablated Mice after Met Inhibition
(A) Quantitative RT-PCR for Met mRNA expression in tumors from NG2-tk+GCV and WT+GCV mice.
(B) Immunostaining of 4T1 tumor for phosphorylated Met (p-Met). Nuclear counterstain: hematoxylin. Scale bar, 50 mm. Quantification of p-Met expression.
(C) Immunostaining and quantification of p-Met (mammary tumors). Nuclear counterstain: hematoxylin. Scale bar, 50 mm.
(D) Representative images of H&E-stained lung sections from MMTV-PyMT/WT and MMTV-PyMT/NG2-tk mice treated with GCV or GCV+PF2341066. Arrows
point to metastatic nodules. Scale bar, 50 mm.
(E) Percent lung metastatic area.
(F) Number of metastatic lung nodules before and after PF2341066 treatment.
Error bars display SEM; asterisks denote significance (*p% 0.05). Scale bar, 50 mm. See also Figure S4.
Cancer Cell
Pericyte and Metastasistissue, pericytes play an important role in regulating the physio-
logical function of blood vessels; however, their precise role in
the context of tumor vasculature is largely unexplored. Studies
related to pericyte coverage on tumor blood vessels suggest
that coverage can vary; some tumor types exhibit greater peri-74 Cancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc.cyte coverage whereas others exhibit limited and abnormal
coverage (Eberhard et al., 2000). Many studies have suggested
that targeting pericytes alone or in combination with endothelial
cells might be beneficial to control tumor growth (Bergers et al.,
2003; Lu et al., 2010; Ozerdem, 2006a, 2006b), while other
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Figure 6. Decreased Pericyte Coverage, Altered Vasculature, Enhanced EMT, and Increased Metastasis in Imatinib- and Sunitinib-Treated
Mice
(A) Orthotopic implantation of 4T1 cancer cells into PBS-, imatinib- and sunitinib-treated mice and tumor volumes over the experimental time course.
(B) Tumor weight at the experimental endpoint.
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Cancer Cell
Pericyte and Metastasisstudies have suggested that pericyte deficiency may facilitate
cancer metastasis (Xian et al., 2006). Our preliminary clinical
studies with tissue samples from patients with invasive ductal
carcinoma suggested that low numbers of vessel-associated
pericytes significantly correlated with poor prognosis. Therefore,
in this study, we explored the function of pericytes in cancer
progression and metastasis.
Tumors in mice generally do not exhibit a significant drop in
pericyte coverage until they reach a very large size (unpublished
data). Therefore, we used multiple transgenic and pharmacolog-
ical approaches to target pericytes and achieve their loss in
tumors of reasonable size. Our data demonstrated that pericyte
loss increasedmetastasis andwas further associatedwith emer-
gence of tumor hypoxia and increased expression of HIF1a. It is
possible that such stromal changes can cooperate with cancer
cell-autonomous changes to enhance metastasis. Met expres-
sion in cancer cells is detected in many advanced stage tumors
including invasive breast cancer (Garcia et al., 2007). We
propose that such induction of Met expression is a result of
increased tumor hypoxia, among other possible mechanisms.
In support of this notion, our results show that tumors without
significant levels of hypoxia exhibit negligible expression levels
of Met and treatment of these tumors with a Met inhibitor has
little impact on their progression.
The reason why a drug such as sunitinib that targets both
endothelial cells and pericytes leads to enhancedmetastasis rai-
ses some questions. We speculate that regardless of their ability
to target endothelial cells, drugs that can target pericytes in
primary tumors, such as sunitinib and sorafenib (Ebos et al.,
2009), may increase metastasis. More studies are required to
clarify these observations, but our studies suggest that pericytes
may serve as negative regulators of metastasis.
It is important to note that increased metastasis is associated
with poor pericyte coverage in the primary tumor. However, if
pericyte are targeted to mimic adjuvant therapy in the clinic, an
increase in metastasis is not observed. In fact, sunitinib treat-
ment of mice after intravenous introduction of RCC results in
decreased metastatic colonization, consistent with the clinical
experience of treating RCC patients with sunitinib as an adjuvant
therapy to control metastasis (Motzer et al., 2007). Collectively,
our data support the notion that sunitinib used in the adjuvant
setting possibly helps to control metastasis of certain cancers
but it might lead to increased metastasis when used in the neo-
adjuvant setting.
One of the challenges in studying the effect of pericyte ablation
on tumor growth and metastasis is that pericytes are reported to(C) Representative images of TUNEL immunofluorescent labeling and quantific
magnification images are shown in the upper right corner. Scale bar, 50 mm.
(D) Representative photomicrographs of H&E-stained lung sections of control a
magnification images of metastatic nodules are located in the upper right corne
nodules.
(E) Representative images and quantitative analysis of extravascular FITC-dextra
(F) Representative immunofluorescent images of staining for pimonidazole addu
(G) Representative immunofluorescent images and quantification of HIF1a expre
(H) EMT was detected in 4T1 tumors of control and treated mice by immunofluore
point to CK8+/aSMA+ double-positive cells. Scale bar, 50 mm. Quantification of E
(I) Quantitative RT-PCR analysis for E-cadherin, Snail, and Twist mRNA expressio
expression.
Error bars display SEM; asterisks denote significance (*p% 0.05). NS, nonsignifi
76 Cancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc.express different markers such as NG2, PDGFRb, aSMA, des-
min, and RGS5 (Bergers and Song, 2005), and their expression
may be tissue specific. During vascular morphogenesis, NG2
is exclusively present on pericytes (as determined by their peri-
vascular location) (Ozerdem et al., 2001b), and NG2 and
PDGFRb share greater than 90% colocalization in the tumor
microenvironment (Sugimoto et al., 2006). Additionally, NG2
and PDGFRb have been repeatedly reported as reliable markers
for pericytes (Bergers and Song, 2005; Hellstro¨m et al., 1999;
Ozerdem et al., 2002; Schlingemann et al., 1990; Sennino
et al., 2007; Xian et al., 2006). It should be noted that in our study
we achieve pericyte ablation using different transgenic mouse
models that use NG2 and PDGFRb promoters. While many
studies have demonstrated the utility of NG2 and PDGFRb to
label pericytes in the tumor, it is possible that other cells are
also identified by these markers. Therefore, despite using the
most useful reagents currently available, one cannot rule out
the possibility of nonpericyte cells contributing to the phenotype
we observe in this study. Nevertheless, our approach of using
multiple distinct strategies offers some confidence that our
observations are related to pericyte targeting.
Our studies demonstrated that depletion of pericytes led to
diminished primary tumor growth associated with decreased
microvessel density (MVD) and hypoxia. Imatinib, which did
not lead to reduced MVD, nevertheless, reduced the number of
vessel-associated pericytes and also led to increased hypoxia
possibly due to altered vascular integrity. The differential effects
on MVD in the setting of the transgenic mouse models versus
imatinib treatment raises the possibility that imatinib targeting
of PDGFRb is subtly distinct from strategies that eliminate prolif-
erating pericytes. We speculate that imatinib treatment may
induce an unknown proangiogenic response to compensate
for the loss of pericytes, which may not be present in the trans-
genic mice. In this regard, we observed more non-vessel-asso-
ciated NG2+ cells in the imatinib-treated tumors when compared
to tumors from NG2-tk+GCV and PDGFRb-tk+GCV mice (data
not shown). Such cells, while not associated with vasculature,
may still potentially offer paracrine support to the defective
vessels in imatinib-treated tumors, leading to vessel retention.
VEGF is a hypoxia and HIF1a-responsive gene and the peri-
cyte-ablated tumors revealed defective vasculature associated
with hypoxia, suggesting that any possible rebound angiogenic
effect due to increased VEGF in these hypoxic tumors does
not overcome the overall disruption of the tumor vasculature
due to pericyte deletion. Interestingly, when VEGF-A is directly
targeted using a mouse VEGF-A antibody in the 4T1 setting oration of the percent TUNEL+ area per visual field. Scale bar, 10 mm. High-
nd treated mice. Scale bar, 10 mm. Arrows point to metastatic areas. High-
r. Scale bar, 50 mm. Percent metastatic area and number of metastatic lung
n. Scale bar, 50 mm.
cts in tumor sections and quantification. Scale bar, 50 mm.
ssion. DAPI = nuclei. Scale bar, 50 mm.
scent staining for Cytokeratin 8 (red) and aSMA (green). DAPI = nuclei. Arrows
MT plotted as percent of CK8+/aSMA+ double-positive cells per visual field.
n from tumor tissues of control and treated mice and plotted as log10 relative
cant. See also Figure S3.
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Figure 7. Suppression of Metastasis in Imatinib-Treated and Sunitinib-Treated Mice after Met Inhibition
(A) 4T1 tumor weight after drug treatment.
(B) Representative images of H&E-stained lung sections from tumor-bearing mice treated with PBS, imatinib+PF2341066, or sunitinib+PF2341066. Arrows point
to metastatic nodules. Scale bar, 10 mm. High-magnification images of metastatic nodules are located in the upper right corner. Scale bar, 50 mm.
(C and D) Quantification of percent metastatic area in the lungs of these mice. Significance (p% 0.05) is denoted by * when comparing PBS+vehicle-treated mice
versus imatinib/sunitinib+vehicle-treated mice and by # when comparing imatinib/sunitinib+vehicle-treated mice versus imatinib/sunitinib+PF2341066-treated
mice.
(E and F) Quantitative RT-PCR for E-cadherin, Twist, and Snail in tumor tissues from imatinib-treated mice with and without PF2341066 treatment.
(G) Hypoxia was detected by immunofluorescent staining of pimonidazole adducts in tumor sections after PF2341066 treatment. Scale bar, 50 mm.
(H) Quantitative analysis of pimonidazole accumulation.
(I) Quantitative analysis of HIF1a expression.
Error bars display SEM; asterisks denote significance (*p% 0.05). NS, nonsignificant. See also Figure S4.
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Pericyte and Metastasisbevacizumab in the context of human renal cell carcinoma,
tumor volume decreases due to the decrease in angiogenesis.
Hypoxia, Met expression, and metastasis, however, are not
increased in this setting. These results suggest that targeting
endothelial cells alonemay leave behind vessels that are normal-
ized (appropriately pruned), while targeting pericytes (alone or incombination with endothelial cells) leads to leaky vasculature,
increased hypoxia, increased Met, increased EMT, and
enhanced metastasis (Carmeliet and Jain, 2011; Tong et al.,
2004).
EMT is considered to be the first step in the metastatic
cascade of carcinoma cells using the same response to migrateCancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc. 77
AC
B Figure 8. Poor Pericyte Coverage and
High Met Expression Is Correlated with
Decreased Survival of Breast Cancer
Patients
(A and B) Disease-free (A) and overall survival (B) of
invasive ductal carcinoma (IDC) patients with
relation to CD31+ vessel-associated NG2 expres-
sion together with Met expression.
(C) Baseline demographics and clinical charac-
teristics associated with CD31+ vessel-associated
NG2 expression and Met expression.
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Pericyte and Metastasisaway from the primary tumors as normal epithelial cells employ
during the development (Acloque et al., 2009; Thiery et al.,
2009). EMT is enhanced by hypoxia and has been implicated
in tumor invasiveness (Kalluri, 2009; Kalluri and Weinberg,
2009; Thiery et al., 2009; Trimboli et al., 2008; Yang et al.,78 Cancer Cell 21, 66–81, January 17, 2012 ª2012 Elsevier Inc.2008). Hypoxia is a classic stress-
induced factor in the tumor microenviron-
ment, and it promotes both cellular quies-
cence and induction of survival pathways
(Xie and Huang, 2003). Hypoxia can tip
a tumor to a more invasive phenotype
via mechanisms of increased extracel-
lular proteases such as MMP2 (Mun˜oz-
Na´jar et al., 2006), invoking induction of
Met activation (Eckerich et al., 2007; Pen-
nacchietti et al., 2003) and EMT (Chen
et al., 2010; Erler et al., 2006). Our results
suggest that pericyte depletion promotes
leaky/hyperpermeable vessels, which
may lead to increased interstitial plasma
exudates, possibly increasing the con-
centration of plasma proteins (including
albumin) in the intratumoral/interstitial
region. Such increase in the intratumoral
plasma volume may increase the intersti-
tial pressure and alter fluid dynamics,
which leads to compression of remain-
ing tumor vessels and decreases the
blood flow (Jain, 1987; Stohrer et al.,
2000). Collectively, such changes lead
to hypoxia and set in motion a series of
events that lead to increased metastasis.
Hypoxia-induced EMT can be prevented
by Met targeting and thus our work
suggests that pericyte targeting could
be combined with Met inhibitors to
achieve a synergistic benefit in controlling
primary tumor growth and metastasis.
This notion is in agreement with previ-
ously published reports where dual inhib-
itors of HGF and VEGFR (XL880 and
XL184) were used (Qian et al., 2009;
You et al., 2011). Patients with invasive
ductal carcinoma who exhibit poor peri-
cyte coverage coupled with high Met
expression revealed a significant drop indisease-free and overall survival. Collectively, our results
suggest that an analysis of pericyte coverage on tumor vessels
coupled with Met expression can serve as a useful biomarker
to inform patient prognosis. More in-depth clinical studies are
required to further evaluate such potential clinical utility.
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Pericyte and MetastasisEXPERIMENTAL PROCEDURES
Cell Lines
4T1 BALB/c mammary tumor epithelial cells, B16F10 C57Bl6 melanoma cells,
and 786-O human renal cell carcinoma cells were obtained from ATCC and
grown in DMEM media supplemented with 10% fetal calf serum (FCS),
100 U/ml penicillin and 100 U/ml streptomycin. 4T1-twist shRNA cells (clones
5 and 7, a gift from Dr. Robert Weinberg, MIT) were cultured in DMEM media
supplemented with 5% heat inactivated FCS, 5% heat activated FCS,
100 U/ml penicillin, and 100 U/ml streptomycin.
Animal Experiments and Immunohistochemistry
Generation of transgenic mice, tumor models, drug treatments, immunohisto-
chemistry, and additional experimental procedures are described in Supple-
mental Experimental Procedures. All animal experiments were reviewed and
approved by the Beth Israel Deaconess Medical Center Institutional of Animal
Care and Use Committee.
Quantitative PCR Analysis
Expression was determined using the Applied Biosystems 7300 Sequence
Detector System and SYBR green as the fluorescence reporter. Measure-
ments were standardized to the housekeeping gene acidic ribosomal phos-
phoprotein PO (ARP/36B4). To assess the number of 4T1-GFP+ cells in the
lung, quantitative PCR for GFP was performed using genomic DNA as
a template. Primer sequences are listed in Supplemental Experimental
Procedures.
Clinical Study
Breast cancer patients were recruited for biopsy at the A. C. Carmargo
Hospital in Sao Paulo, Brazil after approval by the institutional review board
and informed consent. The analysis was performed on 130 biopsies from
patients with invasive ductal carcinoma (IDC). The tissue microarrays (TMAs)
were constructed from 1.50 mm cores of formalin-fixed paraffin-embedded
breast tissue. Immunostaining and scoring of the TMAs for CD31, NG2,
HIF1a, and Met are described in Supplemental Experimental Procedures.
Statistical Analysis
For comparison between two groups, a two-tailed unequal variance t test was
used. Association between clinical characteristics and NG2 or Met expression
levels was verified by a two-tailed Fisher’s exact test. For survival analysis,
Kaplan-Meier curves were drawn and differences between the curves were
calculated by the log-rank test. Independent prognostic significance of HIF1a,
Met and NG2 was computed by the Cox proportional hazards. *p % 0.05
was considered statistically significant. All data analysis was performed using
R software version 2.13.0 (http://www.R-project.org).
ACCESSION NUMBERS
Themicroarray data have been deposited in the Array Express database under
the accession number E-MTAB-525.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2011.11.024.
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